

Fig. 3. Interaction of PP5 with ER α and ER β in Mammalian Two-Hybrid Assays

A. Structure of full-length and truncated mutants of human ER α and ER β . The cDNAs encoding wild-type (WT) ER α and ER β or cDNA fragments encoding structural ABCD domains (amino acids 1–302), ABC domains (amino acids 1–263), E domain (amino acids 302–530), and a part of EF domains (amino acids 530–595) of ER α , and ABCD domains (amino acids 1–248), ABC domains (amino acids 1–213), E domain (amino acids 248–481), and a part of EF domains (amino

vector (Fig. 5A), and the phosphorylation level 5 min after EGF stimulation was 29% reduced relative to control cells (Fig. 5B). The maximal S118 phosphorylation levels induced by either E $_2$ (Fig. 5A) or EGF (Fig. 5B) were approximately 65% and 80% enhanced, respectively, in MCF7 cells transfected with the TPR domains of PP5 compared with control cells. To confirm the inhibitory activity of PP5 on ER α phosphorylation at S118, we investigated the effect of PP5 AS oligonucleotide on the phosphorylation levels of ER α in MCF7 cells. Either E $_2$ -dependent (Fig. 5C) or EGF-dependent (Fig. 5D) phosphorylation of ER α was enhanced by treatment with PP5 AS compared with control mismatch scrambled (Scr) or PP5 sense (Sense) oligonucleotides (~150% increase by 60-min E $_2$ incubation in AS vs. Scr, ~80% increase by 5-min EGF stimulation in AS vs. Scr). The results indicate that PP5 has an inhibitory activity on ER α phosphorylation at S118, and the disruption of PP5 activity either by TPR alone or PP5 AS oligonucleotide causes an enhancement of S118 phosphorylation levels.

Suppression of ER Transcription Activity by PP5

To determine whether PP5 affects estrogen-regulated transcription, we next examined transcriptional activity of ERs and ER mutants using an estrogen response element (ERE)-driven luciferase reporter cotransfected with full-length PP5 or truncated PP5 mutants (Fig. 6). PP5 attenuated the ER transcriptional activity in a concentration-dependent manner, as E $_2$ -dependent transactivations by both ER α and ER β in 293T cells transfected with 50 ng of PP5 were approximately 50% decreased compared with control cells without PP5 transfection (Fig. 6A). Transfection with equal amounts of TPR domain cDNA (5 ng) relative to ER expression vector did not affect E $_2$ -dependent transactivation, whereas 10-fold excess dose of TPR cDNA (50 ng) relative to ER cDNAs elicited a 30–40% increase in E $_2$ -dependent transactivations by both ER α and ER β compared with control cells. Another PP5 mutant with its catalytic domain alone did not affect ER α and ER β transactivations. Because levels of S118 phosphorylation of ER α were modulated by PP5 ex-

acids 481–530) of ER β were subcloned into an expression vector pCMX-GAL4 downstream of and in frame with GAL4 DNA binding domain. **B.** Mammalian two-hybrid assays were carried out using expression vectors of the pCMX-GAL4 containing full-length or mutants of ER α and ER β (GAL4-ER), and pCMX-VP16 containing PP5 (VP16-PP5), in which PP5 was inserted into pCMX-VP16 downstream of and in frame to the VP16 transactivation domain in pCMX-VP16. 293T cells were cotransfected with 0.7 μ g pRL-CMV vector for internal control, 0.8 μ g TK-MH100 \times 4Luc, 0.2 μ g VP16-PP5, and 0.1 μ g each pCMX-GAL4 constructs of ER α or ER β in a well of 24-well plates. The cells were cultured for 24 h and the luciferase assay was performed. Data are the mean \pm SD of three independent experiments performed in triplicate.




Fig. 5. PP5 Inhibits Phosphorylation of ER α on S118 in MCF7 Cells

MCF7 cells were plated at a density of 1.4×10^5 cells per well on six-well plates overnight, transfected with 1 μ g expression plasmids (A and B) or with 1 μ g oligonucleotides (C and D) for 12 h, serum starved for 24 h, and subsequently treated with E₂ (10 nM)(A and C) or EGF (100 ng/ml)(B and D) for indicated times. Cell extracts were collected using 80 μ l of sample buffer for SDS-PAGE. Extracts (25 μ l) were separated by SDS-PAGE and detected by antibody against phosphorylated human ER α on S118 (ER α -P), antibody against whole ER α (H-184), and anti-PP5 antibody (PP5/PPT). A–D, Upper panels show representative data from three independent experiments of Western blots after chemiluminescent detection. A–D, Lower panels show phosphorylation levels at ER α S118 normalized by total protein amounts of ER α . Quantification of signal intensities was performed using LAS 1000 image analyzer, and data are expressed as the mean \pm sd of three independent experiments.

Because S118 phosphorylation levels and ER α transactivation were augmented by treatment with PP5 AS oligonucleotide, we further investigated whether PP5 AS enhances mRNA expression of estrogen-responsive genes (Fig. 8). Transfection with PP5 AS increased basal levels of pS2 (Fig. 8B), *c-myc* (Fig. 8C), and cyclin D1 (Fig. 8D) mRNAs in serum-starved condition (\sim 170%, \sim 100%, and \sim 80% increase for pS2, *c-Myc*, and *CycD1*, respectively; AS vs. Scr). E₂ (10 nM)-induced mRNA expression of those three genes was 25–50% enhanced by PP5 AS compared with PP5 sense or Scr oligonucleotides, without affecting the time course of each gene. The maximal mRNA expression of pS2, *c-myc*, and cyclin D1 detected in 24 h after E₂ stimulation was 25%, 48%, and 36% increased by treatment with PP5 AS, respectively, when compared with Scr oligonucleotide

(at 24 h, 2 h, and 6 h after E₂ stimulation for pS2, *c-Myc*, and *CycD1*, respectively. $P < 0.05$ for pS2 at 24 h, Scr vs. AS; $P < 0.001$ for *c-Myc* at 2 h, Scr vs. AS; $P < 0.05$ for *CycD1* at 6 h, Scr vs. AS).

Taken together, the data demonstrate that PP5 negatively regulates ER phosphorylation levels, transcriptional activity, and transcriptional induction of estrogen-responsive genes.

DISCUSSION

In the present study, we isolated a serine/threonine phosphatase PP5 as a direct interactant with ER β through yeast two-hybrid studies. GST pull-down as-




Fig. 6. Inhibition of ER-Mediated Transcription by PP5

A, 293T cells were plated at a density of 1×10^4 cells per well on 24-well plates and transfected with 0.8 μ g ERE-tk-Luc, 0.7 μ g pRL-CMV, 0–50 ng expression vectors for full-length (PP5), TPR domain (TPR), or catalytic domain (C) of PP5, and 5 ng expression vectors for ER α and ER β . Cells were treated with or without E₂ (10 nM) for 24 h, and luciferase assays were performed. Data are expressed as the mean \pm SD of three independent experiments performed in triplicate. B, 293T cells were transfected with 0.8 μ g ERE-tk-Luc, 0.7 μ g pRL-CMV, 0–50 ng expression vectors for full-length PP5, TPR domain, or catalytic domain (C), and 5 ng expression vectors for wild-type ER α or ER α mutants S118A and S118E. Data are expressed as the mean \pm SD of three independent experiments performed in triplicate. C, Effect of PP5 AS oligonucleotide on ER-mediated transcription. Luciferase assays were performed as in panel B except transfection with 0.8 μ g ERE-tk-Luc, 0.7 μ g pRL-CMV, and 200 ng oligonucleotides into MCF7 cells. *Upper panel* shows the data of three independent experiments performed in triplicate. *Lower panels* show representative data from three independent experiments of Western blots (WB) using the identical cell extracts for luciferase assays. Signals were detected by antibodies against ER α and PP5.




Fig. 7. PP5 Attenuates E₂-Induced Transcription of Estrogen-Responsive Genes in MCF7 Cells
 MCF7 cells were plated at a density of 1 × 10⁶ cells per well on 10-cm plates and infected with recombinant adenoviruses expressing PP5 (Ad-PP5) and GFP (Ad-GFP), or transfected with vehicle (Vehicle) for 12 h at a multiplicity of infection of 10. Cells were serum starved for 24 h after the infection and treated with E₂ (10 nM) for indicated times. Northern blot analysis was carried out using 20 μg total RNA and hybridized with ³²P-labeled cDNAs for pS2, *c-myc*, cyclin D1 (CycD1), and GAPDH. A, The representative result of three independent experiments of Northern blotting. B, C, and D, Quantification of mRNA levels of estrogen-responsive genes including pS2 (B), *c-myc* (C), and CycD1 (D) after normalization to GAPDH mRNA levels in MCF7 cells after E₂ treatment. Data are expressed as the mean ± sd values of fold change over control from three independent experiments. Data for cells treated with vehicle and harvested at the starting point of E₂ treatments are used as control mRNA levels.

says, mammalian two-hybrid assays, and immunoprecipitation studies show that PP5 interacts with both ERα and ERβ through its TPR domains. We demonstrated that PP5 negatively regulates the degree of both estrogen-dependent and EGF-dependent ERα phosphorylation on S118, leading to the suppression of ER transcriptional activity and the reduction of E₂-induced expression of estrogen-responsive genes including pS2, *c-myc*, and cyclin D1. We thus present the first evidence that PP5 acts as an inhibitory regulator of ER signaling pathway in a negative direction.

The status of ER phosphorylation can be regulated by phosphatases, as okadaic acid treatment enhances ERα phosphorylation and ERα transactivation (29). While preparing this manuscript, another member of the PPP family PP2A has been found to interact with ERα and dephosphorylate S118 of the receptor (30). Here we have shown the evidence that ER phosphorylation and function can be modulated by PP5. There are several differences between PP5 and PP2A regarding the interactions with ERs. In our results, the TPR domains of PP5 are the sites responsible for




Fig. 8. PP5 AS Oligonucleotide Enhances E₂-Induced Transcription of Estrogen-Responsive Genes in MCF7 Cells

MCF7 cells were plated at a density of 1×10^6 cells per well on 10-cm plates and transfected with 5 μ g control mismatch Scr, PP5 sense (Sense), or PP5 AS oligonucleotides for 12 h. Cells were serum starved for 24 h after the transfection and treated with E₂ (10 nM) for indicated times. Northern blot analysis was performed as indicated in Fig. 7. A, The representative result of three independent experiments of Northern blotting. B, C, and D. Quantification of mRNA levels of estrogen-responsive genes including pS2 (B), *c-myc* (C), and CycD1 (D) after normalization to GAPDH mRNA levels in MCF7 cells after E₂ treatment. Data are expressed as the mean \pm SD values of fold change over control from three independent experiments. Data for cells transfected with Scr oligonucleotide and harvested at the starting point of E₂ treatments are used as control mRNA levels.

binding to ER α and ER β . The TPR domains of PP5 may also function as an autoinhibitory region against phosphatase activity as removal of the domain produces a marked increase in activity (31). In contrast, PP2A acts in a form of heterotrimer like other members of the PPP family, except PP5, and it has been reported that the catalytic subunit of the phosphatase is required for the interaction with ER α . In regard to interacting functional domains of ERs, we have found E domains not containing an AD core region within AF-2 bind to PP5, whereas the A/B domain within AF-1 of ER α was reported to associate with PP2A. Thus it seems that ERs can be dephosphorylated by several

kinds of protein phosphatases at different functional domains, leading to the more complex and subtle regulatory mechanisms for the receptors. Yet it is also noted that PP5 can exist in a native complex *in vivo* with the A subunit of PP2A via its TPR domains (20). It may be possible that PP5 directly interacts and cooperates with PP2A when the phosphatases bind to ERs and regulate the phosphorylation status of the receptors.

Notably, we showed that the truncated PP5 mutant consisting of only its TPR domains acts as a dominant negative PP5 because it increased the levels of ER α phosphorylation on S118 and transcriptional activation by ER α and ER β . Our data suggest a physiological

role for PP5 in ER signaling *in vivo*. It has been shown that the TPR domains of PP5 also have dominant negative effects on glucocorticoid receptor (GR)-mediated transactivation (16). PP5 could regulate the phosphorylation state of steroid receptors or associated phosphoproteins. We speculate that the TPR domains of PP5 may form complexes with endogenous PP5, leading to inhibition of phosphatase activity of endogenous PP5. Another possibility is that the TPR domains of PP5 displace other interacting proteins of steroid receptors, which are crucial for the regulation of the receptors. Indeed, some of the TPR-containing proteins appear to compete with each other for binding to heat shock protein 90, a major molecular chaperone that forms heterocomplexes with steroid receptors and participates in the signaling pathways of the receptors including glucocorticoid receptor (GR) and ER (32, 33).

To confirm endogenous PP5 activity toward ER α function, we used an AS strategy to decrease PP5 expression in MCF7 cells. The phosphorothioate AS oligonucleotide was designed to target the region overlapping the translation start site. Treatment with PP5 AS oligonucleotide, but not with control Scr or PP5 sense oligonucleotides, led to a significant reduction of PP5 expression (Fig. 6C) and a proportional increase in S118 phosphorylation of ER α (Fig. 5, C and D), transcriptional activity by ER α (Fig. 6C), and expression of estrogen-targeted gene mRNAs (Fig. 8, A–D) in MCF7 cells. In a report using PP5 AS oligonucleotide targeting the 3'-untranslated region of PP5 for MCF7 cells, Urban *et al.* (34) concluded that treatment with up to 500 nM of PP5 AS had no apparent effect on estrogen-induced expression of *c-myc* and cyclin D1 mRNA. In contrast to their Northern blot result, we investigated the time-dependent mRNA expression of estrogen-targeted genes and confirmed that PP5 AS oligonucleotide at a concentration less than 70 nM significantly suppressed E₂-dependent mRNA expression of pS2, *c-myc*, and cyclin D1. Thus, we consider that PP5 is a critical regulator of ER function that could modulate phosphorylation states and transcriptional activities of the receptors.

On the basis of its interactions with other proteins and of studies in which PP5 activity was inhibited using recombinant DNA approaches and antisense oligonucleotide treatment, potential biological roles of PP5 have begun to be elucidated. PP5 has been shown to modulate GR signaling (16, 35), to promote cell growth (34, 36), and to terminate responses to oxidative stress (17). In regard to oxidative stress, PP5 is a physiological inhibitor of apoptosis signal-regulating kinase 1-c-Jun N-terminal kinase/p38 pathway, which plays a pivotal role in stress-induced apoptosis (17). PP5 also interacts with the anaphase-promoting complex and preserves the dephosphorylated or inactivated state of the complex before the activation occurs (19). The growth-promoting effect of PP5 on cell proliferation appears to be exerted by inhibiting both glucocorticoid- and

p53-mediated signaling pathways leading to p21^{WAF1/Cip1}-mediated growth arrest (35, 36). Constitutive overexpression of PP5 in MCF7 cells converted the E₂-dependent phenotype of the cells into an E₂-independent one (34). Indeed, we also observed that adenoviral delivery of PP5 into MCF7 cells increases the number of proliferating cells by cell cycle analysis, as it decreases the percentage of cells at G₁ phase and accumulates the cells at S phase (data not shown). Although it seems paradoxical, we speculate that the proliferative function of overexpressed PP5 observed in MCF7 cells may result from a hyperactivity of the enzyme to inhibit growth-arresting factors including GR and p53, which overcomes PP5-mediated inhibition of ER function at physiological concentrations of the phosphatase.

In summary, we have demonstrated that PP5 directly binds to ERs and regulates ER phosphorylation and transcriptional activity in a negative manner. The inhibitory action of PP5 against ER phosphorylation and function may contribute to a regulatory system of ER-mediated signaling at physiological and pathophysiological status. Further study will be required to understand the distinct activity of PP5 in estrogen-dependent cell proliferation, which may be responsible for developing hormone-dependent tumors.

MATERIALS AND METHODS

Yeast Two-Hybrid Screening

To analyze the regulatory mechanism of ERs, we employed the yeast two-hybrid system to search for proteins that bind to ERs by using ER β (1–481), a truncated human ER β cDNA fragment containing 1–481 amino acids (24) as a bait. The bait plasmid was constructed in-frame with the LexA DNA-binding domain of the pEG202NLS plasmid (Origene Technologies Inc., Rockville, MD). A cDNA library derived from estrogen-depleted MCF7 cells in the pJG4–5 prey plasmid was screened for proteins that interact with ER β (1–481) using the EGY48 yeast reporter strain and the pSH18–34 LacZ reporter plasmid. Plasmids of positive clones were recovered, and the cDNA inserts were sequenced. To examine the interaction between ER β (1–481) and PP5, ER β (1–481) and PP5 constructs were cotransformed along with the pSH18–34 reporter plasmid into the EGY48 yeast strain. Transcriptional activation of LacZ gene was examined in X-gal (5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside)-containing medium. As PP5 cDNA was included in a galactose-inducible vector, pJG4–5, the interaction between ER β (1–481) and PP5 was observed when the reporter yeast was transformed with a ER β (1–481) construct pEG202NLS-ER β (1–481) and cultured in galactose-containing medium.

GST Pull-Down Assay

GST constructs for full-length PP5 (GST-PP5) and truncated PP5 mutants GST-PP5 (2–71), GST-PP5 (28–165), GST-PP5 (2–181), GST-PP5 (2–132), and GST-PP5 (181–499), were prepared in pGEX4T-1 (Amersham Biosciences, Inc., Piscataway, NJ). With regard to structure of the truncated PP5 mutants, GST-PP5 (2–71) includes only one TPR domain. GST-PP5 (28–165) and GST-PP5 (2–181) contain four TPR

domains. GST-PP5 (2–312) consists of four TPR domains plus the N-terminal region of catalytic domain. GST-PP5 (181–499) includes the whole catalytic domain but not TPR domains. GST fusion proteins were induced, solubilized in solution A (20 mM Tris-HCl, pH 7.9; 10% glycerol; 80 mM KCl; 1 mM MgCl₂; 0.2 mM EDTA; 0.5 mM dithiothreitol; 0.5 mM phenylmethylsulfonyl fluoride; and 1% Triton X-100), and bound to glutathione-Sepharose 4B beads following the manufacturer's instruction (Amersham Biosciences, Inc.). GST fusion proteins bound to glutathione beads were incubated at 4 C for 1.5 h with ³⁵S-labeled ER α or ER β , which was synthesized *in vitro* using the TnT-coupled reticulocyte lysate system (Promega Corp., Madison, WI). After the incubation, the beads were washed three times with solution A, and the complexes were separated by SDS-PAGE. The results were visualized using a Fuji FLA 3000 phosphoimaging analyzer (Fuji Film, Tokyo, Japan).

Mammalian Two-Hybrid Assay

The luciferase reporter plasmid TK-MH100 \times 4Luc and the expression plasmids pCMX-GAL4 and pCMX-VP16 were kindly provided by K. Umesono (Kyoto University, Kyoto, Japan). pCMX-VP16-PP5 was constructed by an in-frame ligation of human PP5 cDNA to the VP16 transactivation domain in pCMX-VP16. pCMX-GAL4 constructs were generated by in-frame ligations of various ER α and ER β cDNA fragments to the GAL4 DNA binding domain in pCMX-GAL4. The receptor domains encoded by ER α and ER β cDNA fragments were as follows: for ER α , ABCD (amino acids 1–302), ABC (amino acids 1–263), E (amino acids 302–530), and a part of EF (amino acids 530–595) domains; for ER β , ABCD (amino acids 1–248), ABC (amino acids 1–213), E (amino acids 248–481), and a part of EF (amino acids 481–530) domains. 293T cells were plated at a density of 6×10^4 cells per well of 24-well plates and incubated overnight. Cells were then cotransfected with plasmids containing 0.8 μ g TK-MH100 \times 4Luc, 0.7 μ g pRL-TK vector (Promega), 0.2 μ g VP16-PP5, and 0.1 μ g GAL4 fusion constructs of ER α or ER β using FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN). Cells were cultured for 24 h and luciferase assays were performed using a Dual-Luciferase Assay System (Promega). Data are expressed as the mean \pm SD of three independent experiments performed in triplicate.

Coimmunoprecipitation Assay

The GFP-tagged ER α construct was generated by an in-frame ligation of human ER α cDNA to downstream of GFP in pEGFP-C2 (BD Biosciences CLONTECH, Palo Alto, CA). The Flag-tagged pcDNA3 (Invitrogen, San Diego, CA) constructs pcDNA3-Flag-PP5 and pcDNA3-Flag-TPR were prepared by insertions of full-length PP5 and TPR domains (amino acids 28–165) into pcDNA3 containing Flag tag. 293T cells were plated at a density of 1×10^6 cells per dish in 10-cm dishes and cotransfected with 7.5 μ g GFP-ER α and 7.5 μ g Flag-PP5 or Flag-TPR by the calcium phosphate method. After 24 h, cells were incubated with PBS containing 5 mM hydrophobic lysine-specific cross-linker dithiobis[succinimidyl propionate] (Pierce Biotechnology, Inc., Rockford, IL) at 4 C for 30 min. The reaction was stopped by addition of 100 mM Tris-HCl, pH 7.5, at room temperature for 10 min. Cells were washed with PBS and lysed in immunoprecipitation buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5 mM aprotinin, 0.5 mM phenylmethylsulfonyl fluoride). Lysates were cleared by centrifugation, and protein concentrations were determined by the Bradford method (Bio-Rad Laboratories, Inc., Hercules, CA). For immunoprecipitation, 1 mg of lysates were incubated with 10 μ g of anti-Flag antibody M2 (Sigma Chemical Co., St. Louis, MO) for 3 h at 4 C, and then incubated with 20 μ l of protein G-Sepharose beads (50% vol/vol slurry) (Amersham Biosciences, Inc.) for 90 min at 4 C. The

beads were washed three times with immunoprecipitation buffer and resuspended in 20 μ l of sample buffer for SDS-PAGE. Eluted proteins were subjected to SDS-PAGE, followed by electroblotting onto polyvinylidene difluoride membrane, and probed with antibodies against GFP (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan). The antibody-antigen complexes were detected using the enhanced chemiluminescence system (Amersham Biosciences, Inc.) according to the manufacturer's instruction. In experiments for examining the interaction between endogenous PP5 and ER α , the extracts from MCF7 cells were immunoprecipitated with an anti-PP5 antibody PP5/PPT (BD Biosciences, San Jose, CA) or nonimmune serum and probed by an anti-ER α antibody H-184 (Santa Cruz Biotechnology, Santa Cruz, CA).

Adenoviral Gene Expression

Adenoviral constructs of Flag-tagged human PP5 (Ad-PP5) and GFP-fusion histone H2B (Ad-GFP) were prepared in an adenovirus vector using Adenovirus Expression Vector Kit (Takara Bio Inc., Shiga, Japan) (37, 38). MCF7 cells were infected with the recombinant adenoviruses at a multiplicity of infection (MOI) of 10 for 12 h. The infected cells were serum starved for 24 h in phenol red-free DMEM and treated with 10 nM E₂ in DMEM containing 10% dextran-coated charcoal-treated fetal calf serum (dccFCS) for the indicated times.

Oligonucleotide Treatment

Twenty-three-base phosphorothioate oligonucleotides were prepared by Invitrogen. Sequences for PP5 AS, PP5 sense, and control Scr oligonucleotides were 5'-CTCTCGCCCTC-CGCCATCGCCAT-3', 5'-ATGGCGATGGCGGAGGGCGAGAG-3', and 5'-GCAGTGGCGAGCTGAGAGAGGGG-3', respectively. MCF7 cells were incubated with phenol red-free DMEM containing 10% dccFCS before experiments. Cells were transfected with oligonucleotides using GeneSilencer reagent (GeneTherapy Systems, Inc., San Diego, CA) according to the procedure recommended by the manufacturer. Twelve hours after transfection, cells were fed with serum-starved DMEM, or phenol red-free DMEM containing 10% dccFCS supplemented with or without E₂. Cells were used for experiments involving ER phosphorylation, transactivation, and expression of estrogen target genes.

Transcription Assay of ER

Expression vectors of S118A (HE457) and S118E (HE458) mutants of ER α were the gifts from Dr. P. Chambon (3). N-terminal Flag-tagged pcDNA3 constructs including full-length PP5, TPR domains, and catalytic domain were generated. 293T cells at a density of 1×10^4 cells per well on 24-well plates were transfected with 0.8 μ g ERE-tk-Luc, 0.7 μ g pRL-CMV (Promega), 5 ng of expression vectors for full-length ER α /ER β or ER α mutants, and 0–50 ng of expression vectors for full-length or truncated PP5 in phenol red-free DMEM containing 10% dccFCS using FuGENE 6 transfection reagent (Roche Diagnostics). Twelve hours after transfection, cells were treated with or without 10 nM E₂ for 24 h and luciferase assays were performed. Data were represented as the mean \pm SD of three independent experiments performed in triplicate.

Northern Blot Analysis and Probes

The cDNAs encoding full-length human pS2, human *c-myc*, human cyclin D1, and human GAPDH were cloned by RT-PCR and verified by sequencing. Probes for Northern blot analysis were prepared by labeling the cloned cDNAs with [α -³²P]dCTP using the Random Primer Labeling Kit (Takara

Bio Inc.). Total RNAs (20 μ g) were separated in 1% formaldehyde denaturing agarose gels and transferred to Hybond-NX membranes (Amersham Biosciences, Inc.). Blotted membranes were hybridized with the 32 P-labeled probes in a hybridization buffer (0.1% sodium dodecyl sulfate (SDS), 50% formamide, 5 \times sodium saline citrate (SSC), 50 mM NaPO₄ (pH 6.8), 0.1% sodium pyrophosphate, 5 \times Denhardt's solution, and 50 μ g/ml salmon sperm DNA) at 42 C overnight. Membranes were then washed with 2 \times SSC, 0.1% SDS at 42 C for 30 min and 0.2 \times SSC, 0.1% SDS at 42 C for 30 min. Radioactivities of the signals were quantified using a Fuji FLA 3000 phosphorimaging analyzer (Fuji Photo Film, Tokyo, Japan). The mRNA levels for estrogen-targeted genes at each time point were determined by the signal intensities normalized by that of GAPDH mRNA level in an identical sample. Data for cells treated with vehicle and harvested at the starting point of E₂ treatments are used as control mRNA levels. Data are expressed as the mean \pm SD values of fold change over control from three independent experiments.

Analysis for Phosphorylation State of ER α at S118

MCF7 cells were plated at a density of 1.4×10^5 cells on six-well plates and transfected with 1 μ g of expression plasmids for full-length PP5, TPR domains, or an empty vector for 12 h using FuGENE 6 transfection reagent (Roche Diagnostics). In experiments using oligonucleotides, cells were transfected with PP5 sense, AS, or control mismatch Scr oligonucleotides for 12 h using GeneSilencer reagent. In a preliminary experiment, we confirmed that the transfection efficiency of pEGFP-C1 vector (BD Biosciences CLONTECH) into MCF7 cells was 32% using FuGENE 6 transfection reagent. Transfected cells were serum starved for 24 h and treated with E₂ (10 nM), EGF(100 ng/ml), or vehicles. Cell extracts were subjected to immunoblotting using a specific antibody against phosphorylated ER α at S118 (16J4)(Cell Signaling Technology, Beverly, MA). Quantification of signal intensities was performed using LAS 1000 image analyzer (Fuji Photo Film). Three independent experiments were performed, and phosphorylation levels at ER α S118 were normalized by total protein amounts of ER α .

Cell Cycle Analysis

For flow cytometry analysis, MCF7 cells were transduced with recombinant adenoviruses Ad-PP5 or Ad-GFP. Twelve hours after infection, cells were cultured in serum-depleted medium for 24 h and treated with E₂ (10 nM). Cells were trypsinized, fixed with 70% ethanol, treated with RNase A (100 μ g/ml), and then stained with propidium iodide (10 μ g/ml). Cells were analyzed by FACS Calibur flow cytometer (Becton Dickinson and Co., Mountain View, CA) and the cell-cycle profile was determined using ModFit LT software (Becton Dickinson).

Acknowledgments

We thank Dr. P. Chambon for kindly providing HE457 and HE458 plasmids, and T. Hishinuma, T. Ichikawa, and A. Harashima for their technical assistance.

Received August 9, 2003. Accepted January 27, 2004.

Address all correspondence and requests for reprints to: Satoshi Inoue, Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical School, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan. E-mail: INOUE-GER@h.u-tokyo.ac.jp.

This work was supported in part by grants-in-aid from the Ministry of Health, Labor and Welfare; from the Ministry of

Education, Culture, Sports, Science and Technology of Japan; from Kanzawa Medical Research Foundation; and from Novartis Foundation (Japan) for the Promotion of Science.

REFERENCES

- Muramatsu M, Inoue S 2000 Estrogen receptors: how do they control reproductive and nonreproductive functions? *Biochem Biophys Res Commun* 270:1-10
- Shao D, Lazar MA 1999 Modulating nuclear receptor function: may the phos be with you. *J Clin Invest* 103:1617-1618
- Ali S, Metzger D, Bornert JM, Chambon P 1993 Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. *EMBO J* 12:1153-1160
- Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science* 270:1491-1494
- Tremblay A, Tremblay GB, Labrie F, Giguere V 1999 Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. *Mol Cell* 3:513-519
- Chen D, Pace PE, Coombes RC, Ali S 1999 Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. *Mol Cell Biol* 19:1002-1015
- Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, Ali S 2000 Activation of estrogen receptor α by S118 phosphorylation involves a ligand-dependent interaction with TFIID and participation of CDK7. *Mol Cell* 6:127-137
- Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS 1994 Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. *J Biol Chem* 269:4458-4466
- Joel PB, Traish AM, Lannigan DA 1998 Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. *J Biol Chem* 273:13317-13323
- Barford D, Das AK, Egloff MP 1998 The structure and mechanism of protein phosphatases: insights into catalysis and regulation. *Annu Rev Biophys Biomol Struct* 27:133-164
- Cohen PT 1997 Novel protein serine/threonine phosphatases: variety is the spice of life. *Trends Biochem Sci* 22:245-251
- Chen MX, McPartlin AE, Brown L, Chen YH, Barker HM, Cohen PT 1994 A novel human protein serine/threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. *EMBO J* 13:4278-4290
- Hirano T, Kinoshita N, Morikawa K, Yanagida M 1990 Snap helix with knob and hole: essential repeats in *S. pombe* nuclear protein nuc2+. *Cell* 60:319-328
- Sikorski RS, Boguski MS, Goebel M, Hieter P 1990 A repeating amino acid motif in CDC23 defines a family of proteins and a new relationship among genes required for mitosis and RNA synthesis. *Cell* 60:307-317
- Blatch GL, Lassle M 1999 The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. *Bioessays* 21:932-939
- Chen MS, Silverstein AM, Pratt WB, Chinkers M 1996 The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. *J Biol Chem* 271:32315-32320
- Morita K, Saitoh M, Tobiume K, Matsuura H, Enomoto S, Nishitoh H, Ichijo H 2001 Negative feedback regulation of

- ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. *EMBO J* 20:6028–6036
18. Chinkers M 1994 Targeting of a distinctive protein-serine phosphatase to the protein kinase-like domain of the atrial natriuretic peptide receptor. *Proc Natl Acad Sci USA* 91:11075–11079
 19. Ollendorff V, Donoghue DJ 1997 The serine/threonine phosphatase PP5 interacts with CDC16 and CDC27, two tetratricopeptide repeat-containing subunits of the anaphase-promoting complex. *J Biol Chem* 272:32011–32018
 20. Lubert EJ, Hong Y, Sarge KD 2001 Interaction between protein phosphatase 5 and the A subunit of protein phosphatase 2A: evidence for a heterotrimeric form of protein phosphatase 5. *J Biol Chem* 276:38582–38587
 21. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* 389:753–758
 22. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* 95:927–937
 23. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M 1999 Structure of the ligand-binding domain of estrogen receptor β in the presence of a partial agonist and a full antagonist. *EMBO J* 18:4608–4618
 24. Ogawa S, Inoue S, Orimo A, Hosoi T, Ouchi Y, Muramatsu M 1998 Cross-inhibition of both estrogen receptor α and β pathways by each dominant negative mutant. *FEBS Lett* 423:129–132
 25. Brown AM, Jeltsch JM, Roberts M, Chambon P 1984 Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. *Proc Natl Acad Sci USA* 81:6344–6348
 26. Dubik D, Shiu RP 1992 Mechanism of estrogen activation of c-myc oncogene expression. *Oncogene* 7:1587–1594
 27. Sabbah M, Courilleau D, Mester J, Redeuilh G 1999 Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. *Proc Natl Acad Sci USA* 96:11217–11222
 28. Castro-Rivera E, Samudio I, Safe S 2001 Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. *J Biol Chem* 276:30853–30861
 29. Smith CL 1998 Cross-talk between peptide growth factor and estrogen receptor signaling pathways. *Biol Reprod* 58:627–632
 30. Lu Q, Surks HK, Ebling H, Baur WE, Brown D, Pallas DC, Karas RH 2003 Regulation of estrogen receptor α -mediated transcription by a direct interaction with protein phosphatase 2A. *J Biol Chem* 278:4639–4645
 31. Sinclair C, Borchers C, Parker C, Tomer K, Charbonneau H, Rossie S 1999 The tetratricopeptide repeat domain and a C-terminal region control the activity of Ser/Thr protein phosphatase 5. *J Biol Chem* 274:23666–23672
 32. Owens-Grillo JK, Hoffmann K, Hutchison KA, Yem AW, Deibel Jr MR, Handschumacher RE, Pratt WB 1995 The cyclosporin A-binding immunophilin CyP-40 and the FK506-binding immunophilin hsp56 bind to a common site on hsp90 and exist in independent cytosolic hetero-complexes with the untransformed glucocorticoid receptor. *J Biol Chem* 270:20479–20484
 33. Ratajczak T, Carrello A 1996 Cyclophilin 40 (CyP-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding. *J Biol Chem* 271:2961–2965
 34. Urban G, Golden T, Aragon IV, Scammell JG, Dean NM, Honkanen RE 2001 Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively. *J Biol Chem* 276:27638–27646
 35. Zuo Z, Urban G, Scammell JG, Dean NM, McLean TK, Aragon I, Honkanen RE 1999 Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. *Biochemistry* 38:8849–8857
 36. Zuo Z, Dean NM, Honkanen RE 1998 Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest. *J Biol Chem* 273:12250–12258
 37. Niwa H, Yamamura K, Miyazaki J 1991 Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 108:193–199
 38. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I 1996 Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. *Proc Natl Acad Sci USA* 93:1320–1324



Molecular Endocrinology is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

Association of Multiple Nucleotide Variations in the Pituitary Glutaminyl Cyclase Gene (*QPCT*) With Low Radial BMD in Adult Women

Yoichi Ezura,¹ Mitsuko Kajita,¹ Ryota Ishida,¹ Shoko Yoshida,^{1,2} Hideyo Yoshida,^{3,4} Takao Suzuki,^{3,4} Takayuki Hosoi,^{3,4} Satoshi Inoue,⁵ Masataka Shiraki,⁶ Hajime Orimo,^{3,4} and Mitsuru Emi¹

ABSTRACT: Correlation between 13 genetic variations of the *glutaminyl-peptide cyclotransferase* gene and adjusted aBMD was tested among 384 adult women. Among 13 variations with strong linkage disequilibrium, R54W showed a prominent association ($p = 0.0003$), which was more striking when examined among 309 elder subjects (≥ 50 years; $p = 0.0001$). Contribution for postmenopausal bone loss was suggested.

Introduction: Alterations in homeostatic regulation of estrogen through the hypothalamus-pituitary-gonadal axis (HPG axis) importantly affect the pathogenesis of osteoporosis. Osteoporosis-susceptibility genes have been proposed in this hormonal axis, such as estrogen receptor genes and the gonadotropin-releasing hormone gene (*GnRH*). Here we report another example of genes: glutaminyl-peptide cyclotransferase gene (*QPCT*), an essential modifier of pituitary peptide hormones, including GnRH.

Materials and Methods: Analyses of association of 13 single nucleotide polymorphisms (SNPs) at the *QPCT* locus with adjusted areal BMD (adj-aBMD) were carried out among 384 adult women. Linkage disequilibrium (LD) was analyzed by haplotype estimation and calculation of D' and r^2 . Multiple regression analysis was applied for evaluating the combined effects of the variations.

Results and Conclusions: LD analysis indicated strong linkage disequilibrium within the entire 30-kb region of the *QPCT* gene. Significant correlations were observed between the genotypes of the six SNPs and the radial adj-aBMD, among which R54W (nt + 160C>T) presented the most prominent association ($p = 0.0003$). Striking association was observed for these SNPs among the 309 subjects >50 years of age (R54W, $p = 0.0001$; -1095T>C, $p = 0.0002$; -1844C>T, $p = 0.0002$). Multiple regression analyses indicated that multiple SNPs in the gene might act in combination to determine the radial adj-aBMD. These results indicate that genetic variations in *QPCT* are the important factors affecting the BMD of adult women that contribute to susceptibility for osteoporosis. The data should provide new insight into the etiology of the disease and may suggest a new target to be considered during treatment.

J Bone Miner Res 2004;19:1296–1301. Published online on March 29, 2004; doi: 10.1359/JBMR.040324

Key words: single nucleotide polymorphism, glutaminyl-peptide cyclotransferase gene, pituitary glutaminyl cyclase, BMD, association study, quantitative trait

INTRODUCTION

OSTEOPOROSIS IS A MULTIFACTORIAL common disease characterized by reduced bone mass, microarchitectural deterioration of bone tissue, and increased risk of fragility fractures. Nucleotide variations in several genes that play roles in the pathogenesis of osteoporosis, acting in combination, may explain the complexity of variations in BMD in a population.^(1,2) However, the details of these covariates have not been clarified.

Adequate levels of sex hormones, especially estrogen, are essential for achievement of peak bone mass as well as for postmenopausal maintenance of the skeletal system.⁽³⁾ A hierarchical regulatory system, the hypothalamic-pituitary-gonadal axis (HPG axis), controls serum levels of these hormones.^(4–6) Recently, we showed that an amino acid variation (W16S) in the signal peptide of gonadotropin-releasing hormone (*GnRH*), a primary regulator of the HPG axis, was associated with BMD in postmenopausal women.⁽⁷⁾ Those results suggested that variations in other genes involved in the HPG axis could also affect BMD and influence susceptibility to osteoporosis.

The authors have no conflict of interest.

¹Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, Kawasaki, Japan; ²Department of Molecular Genetic Sciences, Division of Biomedical Laboratory Sciences, Graduate School of Allied Health Sciences, Tokyo Medical and Dental University, Tokyo, Japan; ³Department of Epidemiology, Tokyo Metropolitan Institute of Gerontology and Geriatric Hospital, Tokyo, Japan; ⁴Department of Internal Medicine, Tokyo Metropolitan Institute of Gerontology and Geriatric Hospital, Tokyo, Japan; ⁵Department of Geriatric Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan; ⁶Department of Internal Medicine, Research Institute and Practice for Involuntal Diseases, Nagano, Japan.

TABLE 1. PHYSICAL AND CLINICAL CHARACTERISTICS OF THE 384 SUBJECTS

	Whole	Younger subjects (age \leq 50 years)	Elder subjects (age > 50 years)
Number	384	75	309
Age (years)	58.4 \pm 8.58 (32–69)	44.9 \pm 4.59 (32–50)	61.7 \pm 5.61 (51–69)
Weight (kg)	54.2 \pm 8.91 (28.8–89.0)	56.7 \pm 8.63 (40.5–89.0)	53.6 \pm 8.88 (28.8–84.5)
BMI (kg/m ²)	23.7 \pm 3.61 (14.7–38.5)	23.5 \pm 3.79 (17.5–38.5)	23.7 \pm 3.57 (14.7–37.7)
Height (cm)	151.3 \pm 5.85 (130.5–169.0)	155.3 \pm 5.21 (146–169)	150.4 \pm 5.58 (130.5–163.4)
Raw aBMD (g/cm ²)*	0.399 \pm 0.082 (0.178–0.635)	0.488 \pm 0.060 (0.369–0.635)	0.378 \pm 0.072 (0.178–0.581)
Adjusted aBMD (g/cm ²)†	0.399 \pm 0.054 (0.225–0.554)	0.403 \pm 0.050 (0.280–0.504)	0.398 \pm 0.056 (0.225–0.554)

*Radial BMD was measured by areal scan with DTX-200.

†Raw aBMD data was adjusted with age and BMI by multiple regression analysis.

Active forms of the small peptide hormones secreted by the hypothalamus and pituitary, such as GnRH and thyrotropin releasing hormone (TRH), are susceptible to proteolytic degradation. However, protection from proteolysis occurs in situ, when required, through modification of the N-terminal or C-terminal ends of the peptides.^(8–10) GnRH and TRH are glutamyl peptides in which the N-terminal glutamine residue is associated with histidine in the next position.^(8,11) For protection, an enzyme designated pituitary glutamyl cyclotransferase (QPCT, also known as pituitary glutamyl cyclase; EC 2.3.2.5) converts the N-terminal glutamine of these peptides into the pyroglutamate (5-oxoproline or pyrrolidone carboxylic acid), forming a cyclic amide structure by dehydration.^(8,9) The gene encoding this enzyme (*QPCT*) lies on chromosome 2p22.3, within the region where a quantitative trait locus (QTL) for forearm BMD has been identified in the Chinese population (2p21.1–24)⁽¹²⁾ and near a QTL for spinal BMD identified among whites (2p23–24).⁽¹³⁾ Thus, biological and genetic evidence leads us to hypothesize that differences in bone mass among individuals from the general population might be influenced by common nucleotide variation(s) of the *QPCT* gene.

In the work reported here, we examined the potential involvement of the *QPCT* gene in the pathogenesis of osteoporosis by investigating 13 known polymorphisms and by analyzing linkage disequilibrium (LD) among these variations after constructing haplotypes. Multiple regression analyses were carried out to examine possible associations of genotypes or haplotypes with BMD in 384 Japanese women.

MATERIALS AND METHODS

Subjects

DNA samples were obtained from peripheral blood of 384 unrelated women from the general Japanese population. Mean ages and body mass indices (BMIs) were 58.4 \pm 8.6 years (SD; range, 32–69 years) and 23.7 \pm 3.61 kg/m² (range, 14.7–38.5 kg/m²). The areal BMD of distal radius (expressed in g/cm²) in each participant was measured by DXA using a DTX-200 (Osteometer Meditech, Hawthorne, CA, USA). In this study, we use a specific abbreviation "aBMD" to denote the DXA measurement of the standard "areal BMD" for our results. Although volumetric analysis of BMD was not applied in this study, there were no large

differences in bone size among our study subjects, and the measured aBMD was normalized for differences in age, height, and weight using the Instat 3 software package (GraphPad Software, San Diego, CA, USA) and multiple regression analysis.^(7,14) The adjustment equation for the study subjects was as follows: adj-aBMD (g/cm²) = measured-aBMD (g/cm²) - 0.006375 \times [58.39 - age (years)] + 0.008961 \times [23.65 - BMI (kg/cm²)]. The aBMD in the radius was measured according to the Guidelines for Osteoporosis Screening in a health check-up program in Japan.⁽¹⁵⁾ No participant had medical complications or was undergoing treatment for conditions known to affect bone metabolism, such as pituitary disease, hyperthyroidism, primary hyperparathyroidism, renal failure, adrenal disease, or rheumatic disease, and none were receiving estrogen replacement therapy. The study received institutional review board approval from participating collection sites. All participants were nonrelated volunteers, and written informed consent was obtained from all human subjects.

The effect of sex hormones on changes in BMD may be important during skeletal development and/or during the postmenopausal period.^(16,17) To analyze separately the period when genotypes might contribute most to lowering adj-aBMD, we divided the 384 subjects into younger and older groups: >50 years ($n = 309$) and \leq 50 years ($n = 75$). Basic characteristics of the subjects are summarized in Table 1.

Single nucleotide polymorphism selection and genotyping

Thirteen polymorphic variations of the *QPCT* gene (Table 2) were extracted from the dbSNP of the NCBI (<http://www.ncbi.nlm.nih.gov/SNP/>) and from the JSNP database (<http://snp.ims.u-tokyo.ac.jp/index.html>), spanning almost the entire 30-kb region of the gene locus. Genotypes for nine of these single nucleotide polymorphism [SNPs; IVS1 + 3583C>G, IVS1-3796A>G, IVS1-1629G>C, R54W (nt + 160C>T), IVS2-42A>G, IVS4 + 974G>A, IVS4 + 1053T>C, IVS4-1132C>A, and IVS6 + 73A>G] were determined by the single-base extension method,^(18,19) according to the manufacturer's instructions for the SNaPshot kit (Applied Biosystems, Foster City, CA, USA). In brief, a ~600-bp region of genomic DNA covering the sequence surrounding each of the target SNPs was amplified by a standard PCR program. The PCR products were purified

TABLE 2. SUMMARY OF POLYMORPHISMS ANALYZED AT THE QPCT LOCUS

No.	Name	nt.	Location	dbSNP*
1	-2300C>T	C/T	Promoter	rs952712
2	-1844C>T	C/T	Promoter	rs3755192
3	-1095T>C	T/C	Promoter	rs3755191
4	IVS1+3583C>G	C/G	Intron 1	rs3770753
5	IVS1-3796A>G	A/G	Intron 1	rs3770752
6	IVS1-1629G>C	G/C	Intron 1	rs3770751
7	+126C>T (Y42Y)	taC/taT	Exon 1	rs2302652
8	+160C>T (R54W)	Cgg/Tgg	Exon 2	rs2255991
9	IVS2-42A>G	A/G	Intron 2	rs2302651
10	IVS4+974G>A	G/A	Intron 4	rs3770748
11	IVS4+1053T>C	T/C	Intron 4	rs3770747
12	IVS4-1132C>A	C/A	Intron 4	rs1468816
13	IVS6+73A>G	A/G	Intron 6	rs2287094

*Number from dbSNP database of NCBI (<http://www.ncbi.nlm.nih.gov/SNP/>).

using a separation system (Millipore Japan, Tokyo, Japan) before the single-base primer extension reactions were performed with fluorescence-labeled di-deoxynucleotides (ddNTPs). The extension products were dephosphorylated with shrimp alkaline phosphatase to eliminate co-migration with unincorporated substrates (Roche Japan, Tokyo, Japan). Signals were detected using an ABI377 system and GeneScan Analysis Software vr.2.1 (Applied Biosystems). The Invader assay (Third Wave Technologies, Madison, WI, USA)^(20,21) was used to genotype the other four SNPs (-2300C>T, -1844C>T, -1095T>C, and R54W) according to the manufacturer's protocol. In brief, regions flanking each SNP (e.g., for -2300C>T, a 599-bp region surrounding the SNP to include nucleotides 374132 to 374730 in NT_005367.1) were amplified from 10 ng of genomic DNA by a standard PCR protocol, using the following primer sets: -2300C>T, forward 5'-TGCA-AGCGGCTTTCCAG-3' and reverse 5'-CCTTCATTC-CTTCACATCACAG-3'; -1844C>T, forward 5'-ACAG-CTCCTCTCTTGCTGCC-3' and reverse 5'-CCGCTTG-CAGGAAATCACTC-3'; -1095T>C, forward 5'-TTCC-ACAGTGAGGATCAGGG-3' and reverse 5'-CAGCCAC-TCAGGAAATGCAC-3'; R54W, forward 5'-ACTTAAT-TGGGAGCCTCGGG-3' and reverse 5'-CCTCATTT-GACATAAAGTTCTCCC-3'.

After dilution (1:333) in distilled water, 1 μ l of each product was used as template in a 6- μ l reaction mixture for the Invader assay on 384-well plates, along with appropriate amounts of the probe mix, FRET mix, and Cleavase XI Enzyme in MgCl₂ buffer. The manufacturer provided the designed probe sets along with the required reagents. A 5-minute denaturation was followed by a 60-minute incubation at 63°C in an ABI9700 thermal cycler (Applied Biosystems). No mineral oil was used. The fluorescence signals (for FAM, excitation 485/20 nm and emission 530/25 nm; for Redmond Red, excitation 560/20 nm and emission 620/40 nm) were detected by a CytoFluor 4000 multiwell plate reader (Applied Biosystems). A Hydra microdispenser (Robbins Scientific Corp., Sunnyvale, CA, USA) was used for liquid handling.

Haplotyping, linkage disequilibrium, and statistical analysis

Haplotype frequencies among the 768 alleles investigated were calculated by Arlequine software (Genetics and Biometry Laboratory, Geneva, Switzerland). LD for all possible two-way combinations of the SNPs was tested with D , D' , and r^2 ^(22,23).

Quantitative associations between genotypes and adj-aBMD values (g/cm²) were analyzed by ANOVA with regression analysis as a post hoc test. The three genotypic categories of each SNP (e.g., C/C, C/T, and T/T for rs2255991) were converted into incremental values 0, 1, and 2 respectively. These values corresponded to the number of chromosomes possessing a minor allele of the SNP. Correlation was examined among 384 subjects at first, and then analyzed among younger and older groups separately after dividing the 384 subjects into those >50 years ($n = 309$) and ≤ 50 years ($n = 75$). Significant association was defined when the given p value of the ANOVA F -test was <5% ($p < 0.05$). χ^2 tests were used to ascertain Hardy-Weinberg equilibrium among genotypes ($p > 0.05$). Multiple regression analysis was applied for defining the most significant combination(s) of SNPs that correlate with the adj-aBMD, using Instat 3 software.

RESULTS

We first clarified the allelic frequencies and heterozygosities of the 13 SNPs in QPCT locus by genotyping 384 subjects (Table 3). The maximal likelihood haplotype frequencies estimated by the expectation-maximization algorithm indicated that two major haplotypes covered 66% of the chromosomes in our test population, suggesting strong LD within the locus. Strong LD was verified over the entire gene locus by evaluating the indices of D' and r^2 (Fig. 1).

Analysis on the possible correlations between each SNP and the adj-aBMD revealed that many of the 13 SNPs significantly correlated with adjusted values of forearm aBMD (summarized in Table 3). For example, for SNP -1844C>T, located 1844 bp upstream from the initiation codon ATG (referenced contig NT_005367.1 from GenBank), the minor T allele showed a possible co-dominant effect on lowering adj-aBMD levels ($r = 0.17$, $p = 0.0006$; $n = 384$), because homozygous carriers of the T allele had the lowest adj-aBMD (0.372 ± 0.059 g/cm², $n = 47$), heterozygous individuals had intermediate (0.400 ± 0.055 g/cm²; $n = 177$) adj-aBMD, and homozygous C allele carriers had the highest adj-aBMD (0.406 ± 0.050 g/cm²; $n = 160$; Fig. 2A). When a recessive effect of the minor C allele was assumed, the significance was more impressive ($p = 0.0002$, Student's t -test). Similar but more prominent results were obtained for R54W (+160C>T; $r = 0.18$, $p = 0.0003$; $n = 384$) as well as for the other two SNPs (+126C>T and IVS2-42A>G). Homozygous carriers (R/R) of the major C allele (corresponding to the first nucleotide in an arginine codon, Cgg) had the highest adj-aBMD levels (0.407 ± 0.051 g/cm²; $n = 159$), heterozygous individuals (R/W) had intermediate (0.400 ± 0.056 g/cm²; $n = 177$) levels, and homozygous G allele carriers (W/W) had the lowest adj-aBMD (0.373 ± 0.058 g/cm²;

TABLE 3. SUMMARY OF CORRELATION ANALYSIS

No.	Name	nt.	Allele frequency (heterozygosity)	n*	Correlation coefficient (r^{\dagger})	p Value [‡]
1	-2300C>T	C/T	0.65:0.35 (46.2%)	383	0.17	0.0007
2	-1844C>T	C/T	0.65:0.35 (46.1%)	384	0.17	0.0006
3	-1095T>C	T/C	0.65:0.35 (46.2%)	384	0.17	0.0007
4	IVS1+3583C>G	C/G	0.83:0.17 (27.9%)	384	0.08	NS
5	IVS1-3796A>G	A/G	0.84:0.16 (26.3%)	369	0.01	NS
6	IVS1-1629G>C	G/C	0.95:0.05 (10.0%)	381	0.02	NS
7	+126C>T (Y42Y)	C/T	0.64:0.36 (45.9%)	381	0.19	0.0003
8	+160C>T (R54W)	C/T	0.64:0.36 (45.9%)	384	0.18	0.0003
9	IVS2-42A>G	A/G	0.61:0.39 (43.2%)	370	0.19	0.0003
10	IVS4+974G>A	G/A	0.58:0.42 (49.5%)	382	0.15	0.003
11	IVS4+1053T>C	T/C	0.53:0.47 (50.9%)	383	0.12	0.02
12	IVS4-1132C>A	C/A	0.95:0.05 (8.7%)	381	0.04	NS
13	IVS6+73A>G	A/G	0.55:0.45 (47.2%)	381	0.04	NS

*Number of genotyped subjects.
[†]Absolute values of correlation coefficient.
[‡]p values are calculated for regression analysis with ANOVA F-test.
 NS, not significant.




FIG. 1. Haplotype and linkage disequilibrium analysis of 13 SNPs localized within the QPCT locus. (A) An index of linkage disequilibrium, D' , calculated in every possible pair of the 13 SNPs was indicated in each cell. The D' values >0.5 are highlighted with gray half-tone with gradient. (B) An index of linkage disequilibrium, r^2 , calculated in every possible pair was indicated. The r^2 values >0.1 are highlighted with gray half-tone. These indices were calculated on the base of 17 predicted major haplotypes covering 89% of the chromosomes. (C) The schematic diagram of the QPCT gene structure indicates locations of the eight exons and the 13 tested SNPs by upward arrows.




FIG. 2. Association of R54W variation plotted as adj-aBMD of three genotypically classified subgroups among 384 subjects. Circles indicate mean values, and error bars indicate SD. Correlation between numbers of minor alleles and adj-aBMD (g/cm²) was tested by linear regression analysis (R54W, $r = 0.17$, $p = 0.0003$).

$n = 48$; Fig. 2B). As a whole, four SNPs ($-2300C>T$, $-1844C>T$, $-1095T>C$, and R54W) were likely to have functional significance because of their location and the alteration in the coded amino acids (Table 2).

The implication that combined effects of these SNPs could determine BMD was tested by multiple regression analysis. Although calculations using data from all 13 SNPs estimated a fitting equation that explained $\sim 4.7\%$ of adj-aBMD variances ($r^2 = 0.047$), the statistical level for fitness of the equation was not significant ($p = 0.17$). Thus, an interactive effect among several SNPs was indicated. This assumption was supported by analysis of the data for two selected SNPs (R54W and $-1844C>T$), which yielded a better-fitting equation with statistical significance ($r^2 = 0.033$, $p = 0.0015$), or for three selected SNPs (R54W, $-1844C>T$, and IVS4-1132C>A; $r^2 = 0.038$, $p = 0.0023$). Although the significance levels for these combined analyses were no better than the results obtained for these SNPs singly, we suppose that combined effects of at least two SNPs at the *QPCT* locus might be influencing the radial aBMD in our cohort.

We next tried to define the period when the SNP genotypes might contribute most to lowering adj-aBMD by testing the correlation among younger and older subject groups separately. Significant and consistent correlation was observed for all the SNPs among the older women ($n = 309$), with consistent or better significance levels ($-1844C>T$: $r = 0.23$, $p = 0.00007$; $-1095T>C$: $r = 0.22$, $p = 0.0001$; R54W: $r = 0.21$, $p = 0.0003$), whereas in the younger group of subjects ($n = 75$), we found no significant correlation between any of the SNPs and adj-aBMD. These results may indicate that contribution of these SNPs to acquisition of peak bone mass during the growth period was absent or weak.

DISCUSSION

The work reported here allows us to propose a possible contribution to BMD of polymorphisms in *QPCT*, a novel candidate for osteoporosis susceptibility. Multiple SNPs in this gene revealed significant association with forearm aBMD among adult women from the general population in Japan. Most of these variations were potentially functional, specifically a nonsynonymous coding SNP, R54W (rs2255991), and several SNPs that seemed to be in promoter sequences. *QPCT* may be an important regulator of estrogen levels. Our data implied involvement of these SNPs in determining radial BMD for women >50 years of age.

The *QPCT* gene is a rationally selected candidate, based on its protective function for pituitary peptide hormones⁽⁸⁻¹⁰⁾ and its chromosomal location suggested by QTL analysis in an Asian population.⁽¹³⁾ In addition to the apparent candidacy, our results were intriguing because significant correlation was observed mainly in the polymorphisms whose functions are easily assumed. Among 13 SNPs examined, 3 promoter SNPs and 1 missense SNP, R54W, correlated with adj-aBMD. Although the underlying causative variant cannot be elucidated by the genetics alone because of the high LD in the region of analysis, the informatic motif analysis of the promoter sequence using the MatInspector program⁽²⁴⁾ revealed that the promoter SNP $-1844C>T$ lies within a consensus binding site for estrogen receptors [potential ERE; TGGGACAactTGA(C/T)CGtc].^(25,26) Theoretically, estrogen should regulate expression of multiple target genes involved in the HPG axis^(4,5) through transcriptional activation or repression through estrogen receptors. The *QPCT* gene might be one of those targets. Altered function of the *QPCT* promoter could account for different bone volumes among individuals.

Estrogen is essential for skeletal maturation as well as for maintenance of bone mass in adulthood, especially during the perimenopausal period.^(3,16,17) Therefore, factors involved in estrogen homeostasis may affect bone status through both of the mechanisms generally proposed, that is, low acquisition of peak bone mass before skeletal maturation and unbalanced bone turnover.⁽¹⁾ From our study it is not possible to identify a predominantly contributing mechanism by which the *QPCT* variants may have exerted low BMD in our subjects. However, postmenopausal contribution of these common polymorphisms was implied by the results when subjects were divided into groups above or below age 50, because the association was strikingly significant among the older subjects but absent among the younger women. Further investigations in large cohorts with longitudinal studies will be required.

The mechanism by which certain variants contribute to reduced bone mass is not clear. Despite the LD analysis, where a strong correlation between the missense SNP R54W and the promoter SNP $-1844C>T$ was detected, multiple regression analyses still implied a possibility for the combined effect of regulatory SNPs and a coding SNP in *QPCT* exon 2. Functional analyses should be undertaken to include promoter assays and examination of the enzymatic activities of *QPCT* variants in converting active forms of TRH or GnRH peptides to the protected forms of these

hormones. Reproducible associations among independent cohort(s) should be documented. Nevertheless, our data are the first to indicate a possible contribution of the *QPCT* gene in determining BMD in a general population, and they imply the contribution of multiple polymorphisms within a single gene.

In summary, the results reported here suggest that common polymorphisms in a novel osteoporosis-susceptibility gene, *QPCT*, affect BMD among postmenopausal women in the Japanese population. Because osteoporosis is a multifactorial disease, other genes, especially those involved in regulating levels of sex hormones, should be investigated in this context as well. Such candidates might include cytochrome P450 enzymes, aromatase, steroid hormone hydroxylases, nuclear receptors of steroid hormones, and their target genes or binding factors. The contributions of those factors should clarify the complex mechanism determining BMD in vivo and should help to explain, at least in part, the pathogenesis of postmenopausal osteoporosis. A novel point of view for establishing suitable treatment designs and plans for prevention of the disease could be obtained through such analyses.

ACKNOWLEDGMENTS

We thank Mina Kodaira, Miho Kawagoe, and Mayumi Tanaka for technical assistance and Naoko Tsuruta for editorial assistance. This work was supported in part by a special grant for Strategic Advanced Research on "Cancer" and "Genome Science" from the Ministry of Education, Science, Sports and Culture of Japan; by a Research Grant for Research from the Ministry of Health and Welfare of Japan; and by a Research for the Future Program Grant of The Japan Society for the Promotion of Science.

REFERENCES

- Giguere Y, Rousseau F 2000 The genetics of osteoporosis: "complexities and difficulties." *Clin Genet* **57**:161-169.
- Stewart TL, Ralston SH 2000 Role of genetic factors in the pathogenesis of osteoporosis. *J Endocrinol* **166**:235-245.
- Armamento-Villareal R, Villareal DT, Avioli LV, Civitelli R 1992 Estrogen status and heredity are major determinants of premenopausal bone mass. *J Clin Invest* **90**:2464-2471.
- Herbison AE, Pape JR 2001 New evidence for estrogen receptors in gonadotropin-releasing hormone neurons. *Front Neuroendocrinol* **22**:292-308.
- Kang SK, Choi KC, Tai CJ, Auersperg N, Leung PC 2001 Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. *Endocrinology* **142**:580-588.
- Burns KH, Matzuk M 2002 Genetic models for the study of gonadotropin actions. *Endocrinology* **143**:2823-2835.
- Iwasaki H, Emi M, Ezura Y, Ishida R, Kajita M, Kodaira M, Yoshida H, Suzuki T, Hosoi T, Inoue S, Shiraki M, Swensen J, Orimo H 2003 Association of a Trp16Ser variation in the gonadotropin releasing hormone (GnRH) signal peptide with bone mineral density, revealed by SNP-dependent PCR (Sd-PCR) typing. *Bone* **32**:85-190.
- Busby WH, Quackenbush GE, Humm J, Youngblood WW, Kizer JS 1987 An enzyme(s) that converts glutaminy-peptides into pyroglutamyl-peptides—presence in pituitary, brain, adrenal medulla, and lymphocytes. *J Biol Chem* **262**:8532-8536.
- Fisher WH, Spiess J 1987 Identification of a mammalian glutaminy cyclase converting glutaminy into pyroglutamyl peptides. *Proc Natl Acad USA* **84**:3628-3632.
- Schilling S, Hoffmann T, Rosche F, Manhart S, Wasternack C, Demuth HU 2002 Heterologous expression and characterization of human glutaminy cyclase: Evidence for a disulfide bond with importance for catalytic activity. *Biochemistry* **41**:10849-10857.
- Cummins PM, O'Connor B 1998 Pyroglutamyl peptidase: An overview of the three known enzymatic forms. *Biochim Biophys Acta* **1429**:1-17.
- Niu T, Chen C, Cordell H, Yang J, Wang B, Wang Z, Fang Z, Schork NJ, Rosen CJ, Xu X 1999 A genome-wide scan for loci linked to forearm bone mineral density. *Hum Genet* **104**:226-233.
- Devoto M, Shimoya K, Caminis J, Ott J, Tenenhouse A, Whyte MP, Sereda L, Hall S, Considine E, Williams JC, Tromp G, Kuivaniemi H, Ala-Kokko L, Prockop DJ, Spotila LD 1998 First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. *Eur J Hum Genet* **6**:151-157.
- Kleinbaum DG, Kupper LL, Muller KE 1988 *Applied Regression Analysis and Other Multivariate Methods*, 2nd ed. PWS-KENT Publishing, Boston, MA, USA, pp. 299-301.
- Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara M, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H 2001 Diagnostic criteria for primary osteoporosis: Year 2000 revision. *J Bone Miner Metab* **19**:331-337.
- Riggs BL, Khosla S, Melton LJ III 2002 Sex steroids and the construction and conservation of the adult skeleton. *Endocr Rev* **23**:279-302.
- Riggs BL, Melton LJ III 1986 Involutional osteoporosis. *N Engl J Med* **314**:1676-1686.
- Makridakis NM, Reichardt JK 2001 Multiplex automated primer extension analysis: Simultaneous genotyping of several polymorphisms. *Biotechniques* **31**:1374-1380.
- Iwasaki H, Ezura Y, Ishida R, Kajita M, Kodaira M, Knight J, Daniel S, Shi M, Emi M 2002 Accuracy of genotyping for single nucleotide polymorphisms by a microarray-based single nucleotide polymorphism typing method involving hybridization of short allele-specific oligonucleotides. *DNA Res* **9**:59-62.
- Mein CA, Barratt BJ, Dunn MG, Siegmund T, Smith AN, Esposito L, Nutland S, Stevens HE, Wilson AJ, Philips MS, Jarvis N, Law S, de Arruda M, Todd JA 2000 Evaluation of single nucleotide polymorphism typing with invader on PCR amplicons and its automation. *Genome Res* **10**:330-343.
- Lyamichev V, Mast AL, Hall JG, Prudent JR, Kaiser MW, Takova T, Kwiatkowski RW, Sander TJ, de Arruda M, Arco DA, Neri BP, Brow MA 1999 Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide. *Nat Biotechnol* **17**:292-296.
- Miller PT, Sardina IB, Saccone NL, Putzel J, Laitinen T, Cao A, Kere J, Pilia G, Rice JP, Kwok PY 2000 Juxtaposed regions of extensive minimal linkage disequilibrium in human Xq25 and Xq28. *Nat Genet* **25**:324-328.
- Thompson EA, Deeb S, Walker D, Motulsky AG 1988 The detection of linkage disequilibrium between closely linked markers: RFLPs at the AI-CIII apolipoprotein genes. *Am J Hum Genet* **42**:113-24.
- Quandt K, Frech K, Karas H, Wingender E, Werner T 1995 MatInd and MatInspector: New fast and versatile tools for detection of consensus matches in nucleotide sequence data. *Nucleic Acids Res* **23**:4878-4884.
- Klinge CM 2001 Estrogen receptor interaction with estrogen response elements. *Nucleic Acids Res* **29**:2905-2919.
- Driscoll MD, Sathya G, Myuan M, Klinge CM, Hilf R, Bambara RA 1998 Sequence requirements for estrogen receptor binding to estrogen response elements. *J Biol Chem* **273**:29321-29330.

Address reprint requests to:
Mitsuru Emi, MD, PhD
Department of Molecular Biology
Institute of Gerontology
Nippon Medical School
1-396, Kosugi-cho, Nakahara-ku
Kawasaki 211-8533, Japan
E-mail: memi@nms.ac.jp

Received in original form October 27, 2003; in revised form February 27, 2004; accepted March 29, 2004.

ORIGINAL ARTICLE

Association of a single-nucleotide polymorphism in the promoter region of leukemia inhibitory factor receptor gene with low bone mineral density in adult women

Yoshihiro Sudo,^{1,5} Yoichi Ezura,¹ Ryota Ishida,^{1,5} Mitsuko Kajita,¹ Hideyo Yoshida,² Takao Suzuki,² Takayuki Hosoi,² Satoshi Inoue,³ Masataka Shiraki,⁴ Hajime Orimo,² Hiromoto Ito⁵ and Mitsuru Emi¹

¹Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, Kawasaki, ²Tokyo Metropolitan Institute of Gerontology and Geriatric Hospital, ³Department of Geriatric Medicine, Faculty of Medicine, University of Tokyo, and ⁵Department of Orthopaedics, Nippon Medical School, Tokyo and ⁴Research Institute and Practice for Involuntional Diseases, Nagano, Japan

Background: Osteoporosis is believed to result from the interaction among multiple environmental and genetic determinants that regulate bone-mineral density (BMD).

Methods: To investigate a potentially predisposing genetic factor in the onset of osteoporosis, we looked for a possible association between BMD in adult Japanese women and known polymorphisms in the leukemia inhibitory factor receptor gene (LIFR).

Results: An association analysis of chromosomes from 384 volunteer subjects revealed significant correlation between the -603T > C variant of LIFR and radial BMD ($r = 0.11$, $P = 0.032$) in this test population. Comparisons of mean values of adjusted radial BMD among separate genotypic groups implied an allelic dosage effect, because homozygous carriers of T alleles of that SNP had the highest adjusted BMDs (0.403 ± 0.054 g/cm²); women homozygous for the C-allele had the lowest (0.373 ± 0.042 g/cm²), and heterozygous individuals had intermediate scores (0.394 ± 0.056 g/cm²).

Conclusion: This polymorphism in *LIFR* may be an important determinant of predisposition to postmenopausal osteoporosis.

Keywords: bone mineral density, leukemia inhibitory factor receptor (LIFR), osteoporosis, regression analysis, single-nucleotide polymorphism.

Introduction

Osteoporosis is characterized by low bone-mineral density (BMD) and by deterioration of the microarchitecture of bone tissue, with a consequent increase in fragility and susceptibility to fracture. BMD, an impor-

tant predictor of fracture, is probably determined by genetic as well as environmental factors.^{1,2} Any genes that might affect BMD are candidates for involvement in susceptibility to osteoporosis.

Several genes have already been investigated as potential risk factors for osteoporosis.^{3,4} For example, cytokine pathways that include interleukin-1 (IL1), interleukin-6 (IL6) and tumor-necrosis factor alpha (TNF α) are considered to be among the most potent of all bone-resorbing mechanisms.⁵⁻⁸ However, an extended panel of genes must be examined in detail, in view of the polygenic nature of BMD distribution and the multiplicity of endocrine and local factors that are

Accepted for publication 27 May 2004.

Correspondence: Dr Mitsuru Emi MD, PhD, Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, 1-396, Kosugi-cho, Nakahara-ku, Kawasaki 211-8533 Japan. Email: memi@nms.ac.jp

known to influence bone mass and regulate bone turnover.

The leukemia inhibitory factor (LIF) is one such multifunctional cytokine belonging to the IL-6 family.^{9,10} It affects the differentiation, survival and proliferation of a wide range of cells, including those in bone tissue. For example, adult mice respond to an excess of circulating LIF with increased numbers of osteoblasts, resulting in overgrowth of mineralized bone.¹¹ Therefore, we previously searched for common variations in this gene locus (*LIF*) as a candidate gene for osteoporosis susceptibility.¹⁰ However, since only four variations were detected in the 3'-untranslated region of the third exon in our test samples, we excluded *LIF* from the most likely candidates to be examined for association.

Considerable evidence now indicates that LIF activity in bone exerts significant effects through a high-affinity receptor complex composed of a low-affinity LIF-binding subunit (LIFR) and a converter subunit, gp130.⁹ Targeted disruption of the LIFR gene in mice causes loss of bone density and increasing numbers of osteoclasts.¹ A linkage study on the rare human diseases Stüve-Wiedemann Syndrome (SWS) and Schwartz-Jampel type 2 syndrome (SJS2) representing long bone bowing and cortical thickening with flared metaphyses identified its mutations in the LIFR gene.¹² Given these observations, we hypothesized that LIFR might be one of the most important elements for determining BMD levels in humans.

To investigate a possible association between genetic variations in LIFR and BMD, we examined five single-nucleotide polymorphisms (SNPs) in the promoter region of this gene, and one missense coding SNP, for association with radial BMD levels among adult women in Japan.

Materials and methods

Subjects

DNA samples were obtained from the peripheral blood of 384 Japanese women. All participants were non-related volunteers and gave informed consent prior to

the study. None had medical complications or were undergoing treatment for conditions known to affect bone metabolism, such as pituitary diseases, hyperthyroidism, primary hyperparathyroidism, renal failure or adrenal or rheumatic diseases, and none was receiving estrogen-replacement therapy. Mean ages and body-mass indices (BMI) with standard deviations (SD) were, respectively, 58.4 ± 8.6 years (range, 32–69) and 23.7 ± 3.61 kg/cm² (range, 14.7–38.5).

The BMD (expressed in g/cm²) of each participant was measured in the distal radius by dual-energy X-ray absorptiometry (DEXA) using a DTX-200 osteometer (Meditech Inc., Hawthorne, CA), according to the Guidelines for Osteoporosis Screening in a health check-up program in Japan. To calculate adjusted BMD, measured BMD values were normalized for differences in age and body-mass index (BMI) by multiple regression analysis using the InStat3 software package (GraphPad Software, San Diego, CA).^{13,14} The adjustment equation for the study samples was as follows: (adjusted BMD in g/cm²) = (measured BMD in g/cm²) - 0.006375 × (58.39 - [age in years]) + 0.008961 × (23.65 - [BMI in kg/cm²]).

Genotyping for molecular variants in the LIFR gene

We examined six SNPs (-1226T > C, -631C > T, -603T > C, -264C > T, -210G > C, and +1899 A > G (Ile633Met), all archived in the NCBI database (<http://www.ncbi.nlm.nih.gov/SNP>). All were confirmed to be polymorphic in our test population (Table 1). A contiguous-sequence, NT_023195.12 from RefSeq, was referenced for denoting positions of these SNPs.

Genotypes were determined using the Sd-PCR method, a refined allele-specific PCR, to discriminate polymorphic sequences.¹² In brief, two allele-specific (AS) forward primers and one reverse primer were prepared for each SNP, to transform nucleotide sequences (G, A, T or C) between two alleles at a single site into size-differences. Two different nucleotide mismatches were incorporated at the 3' end of the polymorphic (forward) primers, according to the concept we described elsewhere.¹³ AS primers (long and short) have a

Table 1 Summary of examined polymorphism in the LIFR locus

No	SNP name [†]	JSNP-ID [‡]	dbSNP [§]	Allele frequency	Percent heterozygosity
1	-1226T > C	IMS-JST006591	rs2071233	0.82 : 0.18	30
2	-631C > T	IMS-JST006592	rs2071234	0.81 : 0.19	31
3	-603T > C	IMS-JST006593	rs2071235	0.82 : 0.18	30
4	-264C > T	IMS-JST006594	rs2071236	0.64 : 0.36	41
5	-210G > C	IMS-JST006595	rs2071237	0.67 : 0.33	43
6	Ile633Met	IMS-JST060529	rs2770361	0.96 : 0.04	7

[†]Location of the SNP was defined by NT_023195.12 from RefSeq; [‡]ID number for JSNP database; [§]ID number for dbSNP (NCBI).

five-base difference between them, and each has a polymorphic nucleotide of the SNP sequence at its 3' end as well as having an additional artificial mismatch introduced near the 3' end. The following primer sets allowed distinct discrimination of alleles:

For SNP -210G > C, long AS-primer; 5'-TTTTTG GTAAAAAGCTTTTGCCTCCCGGC-3', short AS-primer; 5'-CCTAAAAAGCTTTTGCCTCCCGGC-3', reverse primer; 5'-GTTTGCTGCTAAGATTACCTAT TGTGG-3'. For SNP -264C > T, Long AS-primer; 5'-TTTTTGGAGCAGTGTGTTTCAGATGGCAG-3', short AS-primer; 5'-CCAGCAGTGTGTTTCAGATG TTAA-3', reverse primer; 5'-GTTTGCTGCTAAGATT ACCTATTGTGG-3'. For SNP -603T > C, Long AS-primer; 5'-TTTTTGGATCCACCTGCCTCGGCCTC GCAA-3', short AS-primer; 5'-CCATCCACCTGCCTC GGCCTCCGAG-3', reverse primer; 5'-GTTTGCT GCTAAGATTACCTATTGTGG-3'. For SNP -631C > T, long AS-primer; 5'-TTTTTGGGGGATGACAGG CGTGAGCTACC-3', short AS-primer; 5'-CCGGGAT GACAGGCGTGAGCCGCT-3', reverse primer; 5'-CCAGGAAAGTTTGCATTGCTAATA-3'. For SNP -1226T > C, long AS-primer; 5'-TTTTTGGCAGTG TAAAATCGCCCTTGCCA-3', short AS-primer; 5'-CCCAGTGAAAATCGCCCTTATCG-3', reverse primer; 5'-GTTTGCTGCTAAGATTACCTATTGTGG-3'. For SNP I633M, long AS-primer; 5'-TTTTTGG TCCCATCCCAACAACCTTGCTCT-3', short AS-primer; 5'-CCTCCCATCCCAACAACCTTGTC-3', reverse primer; 5'-GCTCTAGGTTTATCTAGTTTGA GCA-3'.

Polymerase chain reactions were performed using 10 ng of each genomic DNA sample and 250 nmol/L of each primer (two polymorphic forward, and a reverse) in a 10-μL reaction mixture containing 10 mmol/L dNTPs, 10 mmol/L Tris-HCl, 1.5 mmol/L MgCl₂, 50 mmol/L KCl, 1 U Taq DNA polymerase and 0.5 mmol/L fluorescently labeled dCTP (ROX-dCTP; Perkin-Elmer, Norwalk, CT). The reactions and discrimination of alleles on the ABI Prism 377 DNA system (Applied Biosystems, Foster City, CA) were carried out as described previously.¹³

Statistical analysis

BMD data for each subject were normalized according to age and BMI.¹³ Quantitative associations between genotypes and adjusted BMD values (gm/cm²) were evaluated by one-way ANOVA, with regression analysis as a post-hoc test. Three genotypic categories of each SNP were converted into incremental values (0, 1 and 2) corresponding to the number of chromosomes possessing a minor allele. Statistical significance was determined by ANOVA *F*-tests. We used χ^2 tests to ascertain Hardy-Weinberg equilibrium among genotypes. Haplotypes and indices of linkage disequilibrium (LD) were

calculated using Arlequine software (Genetics and Biometry Laboratory, Geneva, Switzerland).

Results

We examined the LIFR gene for possible association with BMD because it was one of the most likely candidates for involvement in susceptibility to osteoporosis. We first confirmed the polymorphic nature of six archived SNPs in that gene among 32 chromosomes from our test population. Since five SNPs in the promoter region (1226T > C, -631C > T -603T > C, -264C > T, -210G > C) and a non-synonymous coding SNP, +1899 A > G (Ile633Met), were moderately polymorphic, we examined them in our entire panel of 384 subjects and clarified allelic and genotypic frequencies (Table 1). For estimating haplotypes we used only the available genotypic data for the five promoter SNPs in 369 subjects. Results for the missense coding SNP were excluded because its minor allele was so rare (4%). LD within the locus was evaluated by two indices, *D'* and *r*², calculated for every possible combination of the five SNPs (Fig. 1) LD among these SNPs was evident when *D'* > 0.5 and *r*² > 0.15.




Figure 1 Linkage disequilibrium (LD) analysis found significant linkage disequilibrium within the LIFR locus: Indices of LD, *D'* and *r*² based on 17 estimated haplotypes (covering 100% of the chromosomes) constructed with five promoter SNPs were presented in separate tables. *D'* greater than 0.4 and *r*² values greater than 0.1 are highlighted with gray halftone.

Table 2 Regression analysis of adjusted bone mass density (BMD) among 384 screening subjects

SNP Name	<i>n</i> [†]	Adjusted BMD (g/cm ²)			Correlation coefficient (r)	<i>P</i> -value [‡]
		Major homozygous (<i>n</i>)	Heterozygous (<i>n</i>)	Minor homozygous (<i>n</i>)		
-1226T > C	382	0.401 ± 0.054 (256)	0.394 ± 0.056 (115)	0.386 ± 0.048 (11)	-0.07	0.16
-631C > T	383	0.402 ± 0.054 (250)	0.395 ± 0.056 (117)	0.377 ± 0.045 (16)	-0.10	0.054
-603T > C	383	0.403 ± 0.054 (255)	0.394 ± 0.056 (115)	0.373 ± 0.042 (13)	-0.11	0.032
-264C > T	382	0.396 ± 0.055 (167)	0.399 ± 0.049 (155)	0.406 ± 0.064 (60)	0.06	0.28
-210G > C	373	0.401 ± 0.055 (169)	0.398 ± 0.053 (160)	0.400 ± 0.060 (44)	-0.02	0.65
Ile633Met	383	0.400 ± 0.054 (354)	0.395 ± 0.056 (28)	(-)	0.02	0.63

[†]Number of genotyped subjects; [‡]*P*-values are calculated for the regression analysis with ANOVA *F*-test.

Table 3 Summary of characteristics among 383 subjects subgrouped by -603T > C genotypes

	T/T	T/C	C/C	Correlation coefficient (r)
<i>n</i> [†]	255	115	13	NA
Age (year)	58.65 ± 8.68	57.68 ± 8.44	60.23 ± 8.01	0.02
Height (cm)	151.55 ± 6.08	151.55 ± 6.09	151.55 ± 6.10	0.05
Weight (kg)	54.09 ± 9.15	54.57 ± 8.48	54.03 ± 7.80	0.02
Body mass index (kg/cm ²)	23.54 ± 3.70	23.92 ± 3.43	23.97 ± 3.34	0.05

Values are expressed as means ± SDs. Statistical significance for the correlation was tested by ANOVA *F*-test (*P* < 0.05); none of the correlations were statistically significant.

[†]Number of genotyped subjects.

Regression analysis was performed for each SNP by examining correlations between genotypes and adjusted BMDs. Although no significant correlation was evident for five of the six SNPs examined, one promoter SNP (-603T > C) did reveal a significant correlation (*r* = 0.11, *P* = 0.032) (Table 2). Homozygous carriers of the T allele at this site had the highest adjusted BMDs (0.403 ± 0.054 g/cm²); heterozygous individuals were intermediate (0.394 ± 0.056 g/cm²); homozygous C-allele carriers had the lowest adjusted BMDs (0.373 ± 0.042 g/cm²). The apparent allelic-dosage effect of this variation implied a biological influence on BMD. To examine if -603T > C correlate with the other body status, SNP association was tested for multiple clinical features. As indicated, no significant correlation was detected (age, body weight, height, BMI), indicating a specific effect of this SNP on BMD determination (Table 3).

Discussion

In the work reported here we found an association of the -603T > C variation of the LIFR gene with radial BMD in adult Japanese women. Adjusted BMD was highest in homozygous T-allele carriers, intermediate among heterozygotes, and lowest among homozygous C-allele carriers. The data implied that variation(s) in the promoter of LIFR might affect bone metabolism,

eventually introducing variations in BMD among adult women.

Lowered BMD can result from accelerated bone loss and/or lesser acquisition of bone mass.^{1,15} Bone-resorbing effects of cytokine signaling pathways involving IL-1, IL-6, and TNF α have been investigated in vivo and in vitro.⁵⁻⁸ Since members of the IL-6 family, such as LIF, are known to affect the genesis of osteoclasts, promoter variations in the gene encoding the LIF receptor could influence those activities and bring about changes in BMD. Inadequate transcriptional regulation of LIFR in homozygous carriers of the C allele at the -603 position may have led to increased bone loss for those women. We propose that LIF- and LIFR-signaling cascades should be considered in any studies of osteoclastogenesis. Of course, the effects of these molecules on bone formation will need to be clarified as well, because the present study does not address the question of how this particular SNP functionally affects BMD.

In addition to the correlation between one promoter SNP and adjusted BMD in our test population, we demonstrated LD between all five of the promoter SNPs, most significantly between -1226T > C, -631C > T and -603T > C. Although no significant correlation was evident between genotypes of the first two of those three SNPs and adjusted BMD, it remains possible that they can influence regulation of BMD through a combined effect with the -603 site.